e11039 Background: Non-adherence (NAdh) rate to hormonal treatment (HT) has been reported to reach 60%. The goal of this study was to evaluate the level of adherence (Adh) to HT in patients followed in a surgeon's private practice. Methods: From November 2008 to April 2009, all patients with estrogen receptor-positive breast cancer were interviewed at their follow-up visit to the surgeon's office. They were checked for Adh to HT and were asked to detail the reasons for Adh or Nadh. Records were also reviewed for demographics, cancer and treatment characteristics. Qualitative and correlative analyses were carried out. Adh was considered when 100% compliance was reached. Results: Among 398 patients with breast cancer, 161 were eligible: 81% (n = 130) had complete Adh to HT. In patients with Adh, 5 years of HT was completed in 26% (n = 42) and at least 48 months in 36% (n = 58); 52% (n = 88) were ongoing HT at the time of the interview. Median duration on HT was 25 months. Patients reported a unique reason for NAdh (n = 31): forgetting (n = 17); side effects (n = 7); absence of conviction (n = 4); financial problems (n = 1); other acute diseases (n = 1); metastatic disease (n = 1). Patients reported various reasons for Adh: importance of the diagnosis of cancer (100%), fear of recurrence (100%), regular follow-up and supervision by physician and/or nurse (61%), meticulous personality (22%), use of helping device (18%), other medication and/or other medical problems (13%), history of cancer in family and circle (11%), working in the medical or paramedical field (8%), influence of friends and family (5%), inclusion in a research project (3%), and the presence of young children (3%). Multivariate analysis showed that HER2 positivity and postoperative chemotherapy were significantly associated with NAdh (p < 0.05). Conclusions: Adh to HT can be evaluated in a private office practice. Fear of cancer and/or recurrence along with regular follow-up appear to influence Adh to HT. The use of a specific interview to evaluate Adh proved to be a useful tool. Further follow-up and studies should be done to evaluate the relationship between the data and the contribution of regular follow-up by cancer specialist in the Adh to HT. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration AstraZeneca, Genomic Health, Novartis